Abemaciclib + PI3K Inhibitor paxalisib + Entrectinib + Adagrasib
Phase 2Active 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
CDK Gene Mutation
Conditions
CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation, PI3K Gene Mutation, ROS1 Gene Mutation, KRAS G12C Mutation
Trial Timeline
Oct 17, 2019 → Jun 1, 2028
NCT ID
NCT03994796About Abemaciclib + PI3K Inhibitor paxalisib + Entrectinib + Adagrasib
Abemaciclib + PI3K Inhibitor paxalisib + Entrectinib + Adagrasib is a phase 2 stage product being developed by Eli Lilly for CDK Gene Mutation. The current trial status is active. This product is registered under clinical trial identifier NCT03994796. Target conditions include CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03994796 | Phase 2 | Active |
Competing Products
20 competing products in CDK Gene Mutation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CLS-AX + Anti-VEGF | Clearside Biomedical | Phase 1/2 | 33 |
| CLS-AX + Aflibercept | Clearside Biomedical | Phase 2 | 44 |
| Eylea + ALT-L9 | Alteogen | Phase 1 | 33 |
| FYB203 2 mg (0.05 mL of 40 mg/mL) | Formycon AG | Approved | 77 |
| FYB201 0.5 mg (0.05 mL of 10 mg/mL) | Formycon AG | Approved | 77 |
| Latozinemab | Alector | Phase 3 | 69 |
| atomoxetine + placebo | Eli Lilly | Phase 2/3 | 65 |
| UBX1325 injection 50 μL + EYLEA® (aflibercept) Injection 2 mg (0.05mL) | Unity Biotechnology | Phase 2 | 44 |
| Satralizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| YH25448 | Yuhan | Phase 1/2 | 41 |
| YH14618 + YH14618 + YH14618 + Placebo | Yuhan | Phase 1/2 | 41 |
| Placebo + YH14618 | Yuhan | Phase 2 | 52 |
| Quizartinib Dihydrochloride | Daiichi Sankyo | Pre-clinical | 23 |
| DS-7080a + Ranibizumab | Daiichi Sankyo | Phase 1 | 33 |
| Fovista® + bevacizumab + ranibizumab + aflibercept | Astellas Pharma | Phase 2 | 52 |
| MA09-hRPE | Astellas Pharma | Pre-clinical | 23 |
| volociximab | Astellas Pharma | Phase 1 | 33 |
| Avacincaptad Pegol | Astellas Pharma | Phase 1 | 33 |
| ASP0113 | Astellas Pharma | Phase 2 | 52 |
| Avacincaptad Pegol + Avastin + Lucentis + Eylea | Astellas Pharma | Phase 2 | 52 |